Metastatic Colorectal Cancer – Pipeline Review, H2 2016
- Pages: 727
- Published: November 2016
- Report Code: GMDHC8728IDB
Global Markets Direct’s, ‘Metastatic Colorectal Cancer – Pipeline Review, H2 2016’, provides an overview of the Metastatic Colorectal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
The report reviews pipeline therapeutics for Metastatic Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Metastatic Colorectal Cancer therapeutics and enlists all their major and minor projects
The report assesses Metastatic Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
3SBio Inc
AB Science SA
AbbVie Inc
Advenchen Laboratories LLC
Alchemia Ltd
Apexigen Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bavarian Nordic A/S
Bayer AG
Biocon Ltd
Bionomics Ltd
Bionovis SA
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Burzynski Research Institute Inc
Celgene Corp
Celltrion Inc
Cipla Ltd
Coherus BioSciences Inc
Cornerstone Pharmaceuticals Inc
DanDrit Biotech A/S
Dr. Reddy's Laboratories Ltd
EirGenix Inc.
Eisai Co Ltd
Eli Lilly and Company
EnGeneIC Ltd
Etubics Corp
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gene Techno Science Co Ltd
Genor BioPharma Co Ltd
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glycotope GmbH
Hemispherx Biopharma Inc
Hutchison MediPharma Ltd
Ignyta Inc
Immodulon Therapeutics Ltd
Immunomedics Inc
Immunovative Therapies Ltd
Karyopharm Therapeutics Inc
Mabion SA
Mabtech Limited
mAbxience SA
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
MolMed SpA
Mologen AG
Morphotek Inc
Mycenax Biotech Inc
Natco Pharma Ltd
Nektar Therapeutics
Nippon Kayaku Co Ltd
Northwest Biotherapeutics Inc
Novartis AG
OBI Pharma Inc
Oncobiologics Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Pivot Pharmaceuticals Inc
Precision Biologics Inc
PsiOxus Therapeutics Ltd
R Pharm
Regeneron Pharmaceuticals Inc
Richter Gedeon Nyrt
Shanghai Henlius Biotech Co., Ltd.
Shire Plc
Sillajen Biotherapeutics
Symphogen A/S
Synermore Biologics Co Ltd
Taiho Pharmaceutical Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Tocagen Inc
Vaximm AG
XBiotech Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.